The DigniCap Scalp Cooling System and its use in the treatment of chemotherapy-induced alopecia

Future Oncol. 2018 Oct;14(24):2461-2469. doi: 10.2217/fon-2018-0178. Epub 2018 Jul 12.

Abstract

Chemotherapy-induced alopecia remains an emotionally traumatic side effect for cancer patients that impacts the quality of life, may be protracted in duration and may influence treatment decisions. Scalp cooling has been shown to be effective in preventing chemotherapy-induced alopecia. The DigniCap Scalp Cooling System is designed to prevent hair loss by cooling the scalp to reduce the impact of chemotherapy on hair follicle cells. Recent studies have shown the safety, efficacy and low-grade toxicity of the DigniCap System with a 66.3% success rate in hair preservation (n = 106) relative to 0% in a nonrandomized control group according to a prospective pivotal study. Data also support improved quality of life in several domains. Two scalp cooling devices including the DigniCap are now US FDA cleared and can be offered as a part of standard of care.

Keywords: DigniCap; Dignitana; alopecia; cancer patients; cancer symptom management; hair loss; hair preservation; scalp cooling; scalp hypothermia.

MeSH terms

  • Alopecia / chemically induced*
  • Alopecia / prevention & control*
  • Antineoplastic Agents / adverse effects*
  • Humans
  • Hypothermia, Induced / instrumentation*
  • Scalp

Substances

  • Antineoplastic Agents